臨床検査62巻11号

2018年11月発行

今月の特集1 循環癌細胞（CTC）とリキッドバイオプシー

泌尿器科領域におけるリキッドバイオプシーの現状と展望

著者： 桶川隆嗣¹

所属機関： ¹杏林大学医学部泌尿器科

ページ範囲：P.1442 - P.1450

Point

●リキッドバイオプシーはコンパニオン診断として組織生検検査より低侵襲であり，経時的な検体回収が可能である．

●泌尿器科領域では，去勢抵抗性前立腺癌（CRPC）患者における末梢循環癌細胞（CTC）でのアンドロゲン受容体スプライスバリアント（AR-V）7の検出が，治療選択の一助になることが明らかになった．

●現在，AR-V7の検出を臨床の場で応用するには課題も多い．今後はさらに血液中の癌分子・遺伝子診断を行い，適切な治療を選択していく一助になることが望まれる．

●2〜50個ほどのCTC集合体であるCTCクラスターはCTC全体の2〜5％を占め，CTC単独よりもはるかに癌転移を引き起こしやすいことが，各種癌で報告されている．

参考文献

1）Allard WJ, Matera J, Miller MC, et al：Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res　10：6897-6904，2004

2）Cristofanilli M, Budd GT, Ellis MJ, et al：Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med　351：781-791，2004

3）de Bono JS, Scher HI, Montgomery RB, et al：Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res　14：6302-6309，2008

4）Okegawa T, Nutahara K, Higashihara E：Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol　180：1342-1347，2008

5）Okegawa T, Nutahara K, Higashihara E：Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol　181：1091-1097，2009

6）Scher HI, Jia X, de Bono JS, et al：Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol　10：233-239，2009

7）Goldkorn A, Ely B, Quinn DI, et al：Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol　32：1136-1142，2014

8）Scher HI, Beer TM, Higano CS, et al：Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet　375：1437-1446，2010

9）Okegawa T, Itaya N, Hara H, et al：Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res　34：6705-6710，2014

10）Scher HI, Heller G, Molina A, et al：Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol　33：1348-1355，2015

11）Heller G, Fizazi K, McCormack R, et al：The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clin Cancer Res　23：1967-1973，2017

12）Attard G, Swennenhuis JF, Olmos D, et al：Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res　69：2912-2918，2009

13）Haile S, Sadar MD：Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci　68：3971-3981，2011

14）Jenster G, van der Korput HA, van Vroonhoven C, et al：Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol　5：1396-1404，1991

15）Antonarakis ES, Lu C, Wang H, et al：AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med　371：1028-1038，2014

16）Antonarakis ES, Lu C, Luber B, et al：Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol　1：582-591，2015

17）Antonarakis ES, Lu C, Luber B, et al：Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol　35：2149-2156，2017

18）Steinestel J, Luedeke M, Arndt A, et al：Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget doi:10.18632/oncotarget.3925，2015

19）Todenhöfer T, Azad A, Stewart C, et al：AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. J Urol　197：135-142，2017

20）Onstenk W, Sieuwerts AM, Kraan J, et al：Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol　68：939-945，2015

21）Okegawa T, Ninomiya N, Masuda K, et al：AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Prostate　78：576-582，2018

22）Efstathiou E, Titus M, Wen S, et al：Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol　67：53-60，2015

23）Scher HI, Lu D, Schreiber NA, et al：Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol　2：1441-1449，2016

24）Scher HI, Graf RP, Schreiber NA, et al：Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. Eur Urol　71：874-882，2017

25）King JC, Xu J, Wongvipat J, et al：Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet　41：524-526，2009

26）Carver BS, Tran J, Gopalan A, et al：Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet　41：619-624，2009

27）Danila DC, Anand A, Sung CC, et al：TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol　60：897-904，2011

28）Holcomb IN, Young JM, Coleman IM, et al：Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res　69：7793-7802，2009

29）Okegawa T, Itaya N, Hara H, et al：Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. Int J Mol Sci　17：E2008，2016

30）Chaffer CL, Weinberg RA：A perspective on cancer cell metastasis. Science　331：1559-1564，2011

31）Yu M, Bardia A, Wittner BS, et al：Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science　339：580-584，2013

32）Aceto N, Bardia A, Miyamoto DT, et al：Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell　158：1110-1122，2014

33）Beltran H, Jendrisak A, Landers M, et al：The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res　22：1510-1519，2016